Ilevro
Drug
Alcon Research Ltd
Total Payments
$205,916
Transactions
5
Doctors
1
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $205,916 | 5 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $203,466 | 4 | 98.8% |
| Consulting Fee | $2,450 | 1 | 1.2% |
Payments by Type
Research
$203,466
4 transactions
General
$2,450
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5% | Alcon Research Ltd | $203,203 | 0 |
| Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery | Alcon Research Ltd | $263.00 | 0 |
Top Doctors Receiving Payments for Ilevro
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Arcadia, CA | $203,466 | 4 |
| , OD | Optometrist | Lexington, KY | $2,450 | 1 |
Ad
Manufacturing Companies
- Alcon Research Ltd $203,466
- Alcon Laboratories Inc $2,450
Product Information
- Type Drug
- Total Payments $205,916
- Total Doctors 1
- Transactions 5
About Ilevro
Ilevro is a drug associated with $205,916 in payments to 1 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Alcon Research Ltd.
Payment data is available from 2017 to 2017. In 2017, $205,916 was paid across 5 transactions to 1 doctors.
The most common payment nature for Ilevro is "Unspecified" ($203,466, 98.8% of total).
Ilevro is associated with 2 research studies, including "Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%" ($203,203).